WHO guideline aims to facilitate the development of “more durable” pediatric medicines
Regulatory NewsJoanne S. Eglovitch
Chemistry, Manufacturing and Controls (CMC)Clinical TrialsExcipientsGlobalPatient engagementPediatric productsPharmaceuticalsProduct developmentQuality Assurance and ControlRegulatory Intelligence/PolicyWHO